Quality by Design (QbD)-Based Development and Evaluation of Chitosan-Based Sustained Release Tablets of Stavudine
International Journal of Drug Delivery Technology · 08.07.2026 · 16 (63s)
DOI: 10.25258/ijddt.16.63s.26 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 08.07.2026. Verfasst von Gayatri Pattanayak und 5 weiteren Autor:innen.
Abstract (Originalsprache)
The present study aimed to develop and optimize chitosan-based sustained release (SR) tablets of Stavudine using a Quality by Design (QbD) approach to enhance patient compliance and therapeutic efficacy. A Box– Behnken experimental design was employed to systematically evaluate the influence of formulation variables on critical quality attributes. Preformulation studies confirmed acceptable physicochemical properties and high aqueous solubility of Stavudine, necessitating the development of a matrix-based SR system. Tablets were prepared by the wet granulation method using Chitosan, microcrystalline cellulose (MCC), and polyvinylpyrrolidone (PVP) as key formulation components. Fifteen experimental runs were conducted to study the effects of independent variables on tablet hardness, weight variation, and drug release behavior. All formulations complied with pharmacopeial specifications, exhibiting uniform drug content in the range of 95– 99%. In-vitro dissolution studies demonstrated a biphasic drug release pattern extending up to 12 hours, governed primarily by chitosan swelling, MCC-induced matrix porosity, and PVP concentration. Release kinetics followed first-order and Higuchi diffusion models, while Korsmeyer–Peppas analysis indicated a combination of diffusion and erosion mechanisms. Statistical analysis using ANOVA and response surface methodology confirmed the significant influence of formulation variables on tablet performance. The optimized formulation containing Chitosan (134.34 mg), MCC (46.50 mg), and PVP (1.10%) achieved desirable mechanical strength, minimal weight variation, and controlled drug release (~85% at 12 hours). ATR-FTIR and DSC studies verified drug–excipient compatibility and formulation stability. Overall, the QbD-driven development strategy successfully produced a robust sustained release Stavudine tablet, offering reduced dosing frequency, improved patient compliance, and enhanced therapeutic potential.
Zitieren
APA
Pattanayak, G., Khan, A. S., Bhoi, P., Dash, S. K., Padhani, A., & Behera, T. (2026). Quality by Design (QbD)-Based Development and Evaluation of Chitosan-Based Sustained Release Tablets of Stavudine. International Journal of Drug Delivery Technology, 16(63s). https://doi.org/10.25258/ijddt.16.63s.26
Vancouver
Pattanayak G, Khan AS, Bhoi P, Dash SK, Padhani A, Behera T. Quality by Design (QbD)-Based Development and Evaluation of Chitosan-Based Sustained Release Tablets of Stavudine. International Journal of Drug Delivery Technology. 2026;16(63s). doi:10.25258/ijddt.16.63s.26
BibTeX
@article{Pattanayak2026,
author = {Pattanayak, Gayatri and Khan, Abdul Sayeed and Bhoi, Papun and Dash, Santosh Kumar and Padhani, Ashutosh and Behera, Tusarakanta},
title = {Quality by Design (QbD)-Based Development and Evaluation of Chitosan-Based Sustained Release Tablets of Stavudine},
journal = {International Journal of Drug Delivery Technology},
year = {2026},
volume = {16},
number = {63s},
doi = {10.25258/ijddt.16.63s.26}
}
EUVIMED